Home / Articles / Anticancer activity of new 5-(2-oxodihydrobenzimidazolyl)pyrrole-3-carbonitriles, pharmacophore analogues of opnurasib
JUST ACCEPTED ARTICLE. This article has been peer-reviewed and accepted for publication. It is citable and carries a permanent DOI. This version has not been copyedited or typeset and will be replaced by the final version of record.

Anticancer activity of new 5-(2-oxodihydrobenzimidazolyl)pyrrole-3-carbonitriles, pharmacophore analogues of opnurasib

V. R. Galimullina 1, 
V. R. Galimullina
D. V. Ivanova 1, 
D. V. Ivanova
V. V. Syakaev 1, 
V. V. Syakaev
O. B. Babaeva 1, 
O. B. Babaeva
I. Kh. Rizvanov 1, 
I. Kh. Rizvanov
A. A. Zakharchuk 3, 
A. A. Zakharchuk
K. V. Balakin 3*, 
K. V. Balakin
V. A. Mamedov 1*
V. A. Mamedov
Published 15 October 2026 , received 8 July 2026
Communication
0
Cite this
GOST
 | 
Cite this
GOST
Galimullina V. R. et al. Anticancer activity of new 5-(2-oxodihydrobenzimidazolyl)pyrrole-3-carbonitriles, pharmacophore analogues of opnurasib // Mendeleev Communications. 2026.
GOST all authors (up to 50)
Galimullina V. R., Ivanova D. V., Syakaev V. V., Babaeva O. B., Rizvanov I. K., Bunev A. S., Shkil D. O., Zakharchuk A. A., Sinyashin O. G., Balakin K. V., Mamedov V. A. Anticancer activity of new 5-(2-oxodihydrobenzimidazolyl)pyrrole-3-carbonitriles, pharmacophore analogues of opnurasib // Mendeleev Communications. 2026.
RIS
 | 
Cite this
RIS
TY - JOUR
DO - 10.71267/mencom.8142
UR - https://mendcomm.colab.ws/publications/10.71267/mencom.8142
TI - Anticancer activity of new 5-(2-oxodihydrobenzimidazolyl)pyrrole-3-carbonitriles, pharmacophore analogues of opnurasib
T2 - Mendeleev Communications
AU - Galimullina, V. R.
AU - Ivanova, D. V.
AU - Syakaev, V. V.
AU - Babaeva, O. B.
AU - Rizvanov, I. Kh.
AU - Bunev, A. S.
AU - Shkil, D. O.
AU - Zakharchuk, A. A.
AU - Sinyashin, O. G.
AU - Balakin, K. V.
AU - Mamedov, V. A.
PY - 2026
DA - 2026/10/15
PB - Mendeleev Communications
ER -
BibTex
Cite this
BibTex (up to 50 authors)
@article{2026_Galimullina,
author = {V. R. Galimullina and D. V. Ivanova and V. V. Syakaev and O. B. Babaeva and I. Kh. Rizvanov and A. S. Bunev and D. O. Shkil and A. A. Zakharchuk and O. G. Sinyashin and K. V. Balakin and V. A. Mamedov},
title = {Anticancer activity of new 5-(2-oxodihydrobenzimidazolyl)pyrrole-3-carbonitriles, pharmacophore analogues of opnurasib},
journal = {Mendeleev Communications},
year = {2026},
publisher = {Mendeleev Communications},
month = {Oct},
url = {https://mendcomm.colab.ws/publications/10.71267/mencom.8142},
doi = {10.71267/mencom.8142}
}
Views
44

Abstract

This paper describes the molecular design, synthesis, and in vitro anticancer testing results of two novel pharmacophore analogues of opnurasib were obtained, for which molecular docking results predicted high inhibitory activity against the GTPase KRAS G12C. A synthetic approach previously developed in our group was used, which allows for the efficient production of target compounds in two stages from commercially available precursors. In vitro anticancer testing results showed that the obtained compounds exhibit moderate cytotoxic activity (IC50 16–23 µM) against the NCI-H358 cell line with the target KRAS G12C mutation, while exhibiting some selectivity against the AsPC-1 cell line with the non-target KRAS G12D mutation (IC50 >50 µM).

Keywords

a-(benzimidazol-1-yl)pyrroles
acrylamides
KRAS inhibitors
molecular docking
pyrrole-3-carbonitriles
α-(piperazino)pyrroles